PDCD1 and cancer: For example, Kim et al. found that LHRH-R-targeted lytic peptide could enhance cancer immunotherapy in combination with PD-1 antibodies by increasing the population of CD8+ T cells, NK cells, dendritic cells, and macrophages in tumors.